These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 11322061

  • 1. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
    Mulkay JP, Louis H, Donckier V, Bourgeois N, Adler M, Deviere J, Le Moine O.
    Acta Gastroenterol Belg; 2001; 64(1):15-9. PubMed ID: 11322061
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study.
    Halimi C, Bonnard P, Bernard B, Mathurin P, Mofredj A, di Martino V, Demontis R, Henry-Biabaud E, Fievet P, Opolon P, Poynard T, Cadranel JF.
    Eur J Gastroenterol Hepatol; 2002 Feb; 14(2):153-8. PubMed ID: 11981339
    [Abstract] [Full Text] [Related]

  • 5. Terlipressin in hepatorenal syndrome: Evidence for present indications.
    Rajekar H, Chawla Y.
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
    [Abstract] [Full Text] [Related]

  • 6. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
    von Kalckreuth V, Glowa F, Geibler M, Lohse AW, Denzer UW.
    Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
    Krag A, Borup T, Møller S, Bendtsen F.
    Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
    [Abstract] [Full Text] [Related]

  • 10. Terlipressin therapy for renal failure in cirrhosis.
    Triantos CK, Samonakis D, Thalheimer U, Cholongitas E, Senzolo M, Marelli L, Leandro G, Patch D, Burroughs AK.
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
    [Abstract] [Full Text] [Related]

  • 11. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
    Narahara Y, Kanazawa H, Sakamoto C, Maruyama H, Yokosuka O, Mochida S, Uemura M, Fukui H, Sumino Y, Matsuzaki Y, Masaki N, Kokubu S, Okita K.
    J Gastroenterol; 2012 Mar; 47(3):313-20. PubMed ID: 22038555
    [Abstract] [Full Text] [Related]

  • 12. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
    Neri S, Pulvirenti D, Malaguarnera M, Cosimo BM, Bertino G, Ignaccolo L, Siringo S, Castellino P.
    Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.
    Moreau R, Durand F, Poynard T, Duhamel C, Cervoni JP, Ichaï P, Abergel A, Halimi C, Pauwels M, Bronowicki JP, Giostra E, Fleurot C, Gurnot D, Nouel O, Renard P, Rivoal M, Blanc P, Coumaros D, Ducloux S, Levy S, Pariente A, Perarnau JM, Roche J, Scribe-Outtas M, Valla D, Bernard B, Samuel D, Butel J, Hadengue A, Platek A, Lebrec D, Cadranel JF.
    Gastroenterology; 2002 Apr; 122(4):923-30. PubMed ID: 11910344
    [Abstract] [Full Text] [Related]

  • 15. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
    Sharma P, Kumar A, Shrama BC, Sarin SK.
    Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
    [Abstract] [Full Text] [Related]

  • 16. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome.
    Saner F, Kavuk I, Lang H, Biglarnia R, Frühauf NR, Schäfers RF, Malagó M, Broelsch CE.
    Eur J Med Res; 2004 Feb 27; 9(2):78-82. PubMed ID: 15090293
    [Abstract] [Full Text] [Related]

  • 17. Terlipressin therapy for reversal of type 1 hepatorenal syndrome: a meta-analysis of randomized controlled trials.
    Sagi SV, Mittal S, Kasturi KS, Sood GK.
    J Gastroenterol Hepatol; 2010 May 27; 25(5):880-5. PubMed ID: 20074149
    [Abstract] [Full Text] [Related]

  • 18. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I, Durand F, Pessione F, Rassiat E, Bernuau J, Barrière E, Lebrec D, Valla DC, Moreau R.
    J Gastroenterol Hepatol; 2002 Aug 27; 17(8):882-8. PubMed ID: 12164964
    [Abstract] [Full Text] [Related]

  • 19. Hepatorenal syndrome. Long-term treatment with terlipressin as a bridge to liver transplantation.
    Ganne-Carrié N, Hadengue A, Mathurin P, Durand F, Erlinger S, Benhamou JP.
    Dig Dis Sci; 1996 Jun 27; 41(6):1054-6. PubMed ID: 8654133
    [Abstract] [Full Text] [Related]

  • 20. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
    Rodríguez E, Elia C, Solà E, Barreto R, Graupera I, Andrealli A, Pereira G, Poca M, Sánchez J, Guevara M, Soriano G, Alessandria C, Fernández J, Arroyo V, Ginès P.
    J Hepatol; 2014 May 27; 60(5):955-61. PubMed ID: 24447876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.